Shilpa Medicare is currently trading at Rs. 653.00, up by 27.05 points or 4.32% from its previous closing of Rs. 625.95 on the BSE.
The scrip opened at Rs. 651.40 and has touched a high and low of Rs. 658.00 and Rs. 644.70 respectively. So far 6014 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 786.75 on 21-Dec-2016 and a 52 week low of Rs. 525.00 on 09-Nov-2016.
Last one week high and low of the scrip stood at Rs. 658.00 and Rs. 570.00 respectively. The current market cap of the company is Rs. 5208.25 crore.
The promoters holding in the company stood at 54.74%, while Institutions and Non-Institutions held 31.89% and 13.37% respectively.
Shilpa Medicare has received Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its generic pharmaceutical manufacturing facility at Jadcherla in Telangana, India which was inspected between July 24 and July 28 2017.
The inspection has now been closed by the USFDA. The company had submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines in response to the form 483 issued at the end of inspection. The USFDA has reviewed the CAPA and has found them acceptable.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.3
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: